OBJECTIVES: To determine cost-effectiveness and cost-utility of DAA added to standard care compared to standard care in the treatment of severe sepsis with MOF from public payer’s perspective in Poland. METHODS:  Results of a systematic review of published clinical trials conducted according to Polish HTA Guidelines were used to assess effectiveness and safety of DAA. Data on reduction of 28-day all-cause mortality and probability of adverse events for patients treated with DAA or with standard treatment reported in this study, baseline mortality of sepsis patients in Poland, probability of death during four years following intensive care and life tables for general population were incorporated into the decision tree model. A 24-year analytic horizon was established as life expectancy in general population of the same age and gender characteristics as sepsis patients. Epidemiology data were obtained from Polish Sepsis Registry. Cost-utility analysis was performed using utilities for sepsis patients and general population - derived from published literature. Costs of treatment valid from public payer’s perspective were taken into account. Costs of DAA, intensive care unit hospitalization, parenteral nutrition, physician consultations, bleeding and thrombotic events were included. All calculations were performed for 2007 (1EUR=3.8PLN). Only effects were discounted (at 5% rate), as no costs occur beyond 1 year. Sensitivity analysis was conducted assuming range of cost for DAA, length of ICU stay, length of parenteral nutrition and discount rate for effects. RESULTS: Adding DAA to standard therapy of patients with severe sepsis and MOF significantly reduces 28-day mortality. Cost-effectiveness ratios are below the established thresholds (ICER=42,517PLN, ICUR=58,615PLN). Sensitivity analysis showed that these results are robust. CONCLUSIONS:DAA added to conventional treatment of severe sepsis with two or more organ dysfunctions is cost-effective from polish public payer’s perspective.